Theravance Inc. (THRX) announced after the bell Thursday that it received a letter from the FDA indicating that Theravance's response to the November 2009 Complete Response letter for the telavancin New Drug Application for is incomplete and that the review clock will not start until the FDA receives a complete response. The stock is now trading lower by 1.49 on 18K shares.
Theravance Inc. fell in early trade Thursday, but settled into a narrow range for the majority of the session. The stock finished down by 0.35 at $13.50.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.